The Treatment of Tuberculosis in HIV-Infected Patients
Status:
Completed
Trial end date:
1997-07-01
Target enrollment:
Participant gender:
Summary
PER 5/30/95 AMENDMENT: To compare the combined rate of failure during therapy and relapse
after therapy between two durations of intermittent therapy (6 versus 9 months) for the
treatment of pulmonary tuberculosis (TB) in HIV-infected patients. To compare toxicity,
survival, and development of resistance in these two regimens.
ORIGINAL: To compare the efficacy and safety of induction and continuation therapies for the
treatment of pulmonary TB in HIV-infected patients who are either from areas with known high
rates of resistance to one or more anti-TB drugs or from areas where TB is expected to be
susceptible to commonly used anti-TB drugs.
PER 5/30/95 AMENDMENT: In HIV-negative patients, intermittent anti-TB therapy has been shown
to be as effective as daily therapy, but the optimal duration of therapy in HIV-infected
patients has not been established.
ORIGINAL: In some areas of the country, resistance to one or more of the drugs commonly used
to treat TB has emerged. Thus, the need to test regimens containing a new drug exists.
Furthermore, the optimal duration of anti-TB therapy for HIV-infected patients with TB needs
to be determined.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)